In contrast, in ABC DLBCL, this specific activation is not associated with PTEN loss, which implies that there may be a different mechanism underlying PI3K/Akt/mTOR pathway activation in each DLBCL subtype [31]. This evidence concerns the gene MTOR and diffuse large B-cell lymphoma.